AI Generated
Jun 28, 2026, 09:55
Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients
Utkarsh Pandey, Principal Study Data Manager Leader at Sanofi, shared a post on LinkedIn:
“Exciting news!
Wayrilz (rilzabrutinib) has received approval in Japan for the treatment of immune thrombocytopenia (ITP).
This approval is supported by the LUNA 3 phase 3 study, which demonstrated rapid and durable platelet response. It is a significant milestone for patients managing this rare, complex immune disease.”
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments